Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.54 | -0.05 | -0.02 | 0.68 |
| FCF Yield | -4.06% | -20.67% | -13.72% | 0.68% |
| EV / EBITDA | -19.34 | -3.05 | -5.23 | -22.26 |
| Quality | ||||
| ROIC | -40.51% | -62.53% | -29.42% | -7.23% |
| Gross Margin | 92.99% | 90.87% | 96.30% | 96.36% |
| Cash Conversion Ratio | 0.72 | 0.86 | 0.79 | -0.27 |
| Growth | ||||
| Revenue 3-Year CAGR | 92.08% | -32.62% | – | – |
| Free Cash Flow Growth | 31.22% | -148.29% | -1,666.60% | 114.64% |
| Safety | ||||
| Net Debt / EBITDA | 0.21 | 1.47 | 0.87 | 12.87 |
| Interest Coverage | -15.36 | -42.78 | -28.52 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 4.90 | 0.51 | 0.20 | 0.00 |
| Cash Conversion Cycle | -618.95 | -3,075.95 | -230.57 | -501.79 |